68GA-PSMA — LABELED BIOMARKER FOR POSITRON EMISSION TOMOGRAPHY (LITERATURE REVIEW)
https://doi.org/10.18705/2311-4495-2018-5-5-46-52
Abstract
The review is devoted to the analysis of the diagnostic efficiency of combined positron emission and computed tomography (PET / CT) with the radiopharmaceutical 68Ga-PSMA in the initial staging of prostate cancer in middle- and high-risk patients, the determination of the tumor focus in the biochemical recurrence of the disease, and monitoring the effectiveness of systemic and radionuclide therapy. The causes of false positive and false negative results of PET / CT are listed and indications for the procedure are presented as well. 68Ga-PSMA diagnostic possibilities as a labeled biomarker of neovascularization in malignant neoplasms of other localizations are briefly described.
About the Authors
M. D. Poyda
Almazov National Medical Research Centre, Saint Petersburg
Russian Federation
a fellow of the Department of Nuclear Medicine and Theranostics
Russian Federation
a fellow of the Department of Nuclear Medicine and Theranostics
D. V. Ryzhkova
Almazov National Medical Research Centre, Saint Petersburg
Russian Federation
MD, PhD, professor, Researcher of the Department of Nuclear Medicine and Theranostics
Russian Federation
MD, PhD, professor, Researcher of the Department of Nuclear Medicine and Theranostics
A. A. Stanzhevsky
1 Almazov National Medical Research Centre, Saint Petersburg
2 Federal State Budgetary Institution “Granov Russian Scientific Centre of Radioligy and Surgical Technology” of the Ministry of Health of the Russian Federation, Saint Petersburg
Russian Federation
a professor of the course of Nuclear Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia; MD, PhD, deputy director of science, Federal State Budgetary Institution “Granov Russian Scientific Centre of Radioligy and Surgical Technology” of the Ministry of Health of the Russian Federation
Russian Federation
a professor of the course of Nuclear Medicine, Almazov National Medical Research Centre, Saint Petersburg, Russia; MD, PhD, deputy director of science, Federal State Budgetary Institution “Granov Russian Scientific Centre of Radioligy and Surgical Technology” of the Ministry of Health of the Russian Federation
References
1. Wang HL, Wang SS, Song WH, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015;10:e0125924. https://doi.org/10.1371/journal.pone.0125924
2. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians [Internet]. American Cancer Society; 2015 Feb 4;65(2):87–108. http://dx.doi.org/10.3322/caac.21262
3. NCCN Guidelines: Prostate Cancer. Fort Washington, Pennsylvania: National Comprehensive Cancer Network 2018
4. Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–230.
5. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.
6. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006; 26: 5310-24. http://dx.doi.org/10.1128/mcb.00084-06
7. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39. http://dx.doi.org/10.1002/jcb.10661
8. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–62
9. Lütje S, Heskamp S, Cornelissen AS, et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015;5(12):1388–401. http://dx.doi.org/10.7150/thno.13348
10. Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur. J. Nucl. Med. Mol. Imag. 45, 471-495. http://dx.doi.org/10.1007/s00259-017-3882-2
11. Eder M, Schafer M, Bauder-Wust U, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.http://dx.doi.org/10.1021/bc200279b
12. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. http://dx.doi.org/10.1007/s00259-012-2298-2
13. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705. http://dx.doi.org/10.2967/jnumed.115.161299
14. Herrmann K, Bluemel C, Weineisen M, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61. http://dx.doi.org/10.2967/jnumed.115.156133
15. FendlerWP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for PC imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24. http://dx.doi.org/10.1007/s00259-017-3670-z
16. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. http://dx.doi.org/10.1007/s00259-013-2525-5
17. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. http://dx.doi.org/10.1007/s00259-014-2949-6
18. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–674. http://dx.doi.org/10.2967/jnumed.115.154153
19. Eiber M, Pyka T, Okamoto S, et al. 68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients. European Urology Supplements. March 2016;15(3). http://dx.doi.org/10.1016/s1569-9056(16)60568-7
20. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging in Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195(5):1436-43. http://dx.doi.org/10.1016/j.juro.2015.12.025
21. Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? EurJNuclMedMolImaging. 2015;42:1284–94. http://dx.doi.org/10.1007/s00259-015-3078-6
22. Rauscher I, Maurer T, Fendler WP, et al. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. 2016;16:14. http://dx.doi.org/10.1186/s40644-016-0072-6
23. Krohn T, Verburg FA, Pufe T, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42(2):210–214. doi: 10.1007/s00259-014-2915-3
24. Benešová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of PC. JNuclMed. 2015;56:914–920. http://dx.doi.org/10.2967/jnumed.114.147413
25. Baum RP, Wahl RL. Third Theranostics World Congress on Gallium-68 and PRRT: Abstracts. J Nucl Med. 2015;56(Suppl 2):2A–30. http://dx.doi.org/10.2967/jnm565abs
26. Backhaus P, Noto B, Avramovic N, et al. Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging. Springer Nature; 2018 Jan 15;45(5):860–77. http://dx.doi.org/10.1007/s00259-017-3922-y
27. Denmeade SR, Mhaka AM, Rosen DM et al. Engineering a prostate‐specific membrane antigen‐activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012;4:140ra186 10.1126/scitranslmed.3003886 http://dx.doi.org/10.1126/scitranslmed.3003886
28. Pyka T, Weirich G, Einspieler I, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med. 2016;57:367–71. http://dx.doi.org/10.2967/jnumed.115.164442
29. Wang HL, Wang SS, Song WH, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015;10:e0125924. https://doi.org/10.1371/journal.pone.0125924
Review
For citations:
Poyda M.D., Ryzhkova D.V., Stanzhevsky A.A. 68GA-PSMA — LABELED BIOMARKER FOR POSITRON EMISSION TOMOGRAPHY (LITERATURE REVIEW). Translational Medicine. 2018;5(5):46-52. (In Russ.) https://doi.org/10.18705/2311-4495-2018-5-5-46-52
Views:
1581
Email this article 